Biopharma, virtual companies, niched markets and generic drugs have created a radically changing landscape in contract development and manufacturing. Are there critical skills that a contract partner must have that will help their customers compete and be successful?
Many companies are improperly using the term “CDMO” to define their business model because it suggests that they can help their customer maximize the potential of their compound from the earliest stages of drug development through to commercialization. But as Peter Soelkner, managing director of Vetter explains in the August issue of “Pharmaceutical Manufacturing”, before a manufacturer can make such a claim they must have very specific skills, especially those that can add value throughout the product lifecycle. Learn what these necessary skills are.